论文部分内容阅读
重组合人类红细胞生成素(recombinant Humanerythropoietin,rHuEpo)的初步临床研究表明,这种激素对贫血的透析患者可能有效将成为事实。为此,本文综述了慢性肾衰(CRF)贫血的病理生理学及红细胞生成素(Epo)的生理学,以及简述 rHuEpo 的分离和生产技术、临床研究等问题。CRF 贫血的病理生理学历来认为 CRF 贫血是 Epo 缺乏、红细胞(RBC)寿命缩短及红骨髓或Epo 受尿毒症毒素抑制所致。用 rHuEpo 在血透患
Preliminary clinical studies with recombinant human erythropoietin (rHuEpo) have shown that it is a fact that this hormone may be effective in anemic dialysis patients. Therefore, this article reviews the pathophysiology of chronic renal failure (CRF) anemia and the physiology of erythropoietin (Epo), as well as the isolation, production and clinical studies of rHuEpo. The pathophysiology of CRF anemia has historically been characterized by a lack of Epo in CRF anemia, a shortened life span of red blood cells (RBCs), and inhibition of uremia to red marrow or Epo. Use rHuEpo in hemodialysis patients